MedTrace Logo

A First-in-Human Study With XAB05 in Healthy Subjects

NCT05307406 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-08-12

No results posted yet for this study

Summary

This study is a randomized, placebo-controlled, first in human, single ascending dose Phase 1 study

Conditions

  • Infection, Bacterial

Interventions

BIOLOGICAL

Experimental

Participants will receive a single IV infusion in a double blind manner

Sponsors & Collaborators

  • QPS Netherlands B.V.

    collaborator INDUSTRY

  • Xenothera SAS

    lead INDUSTRY

Principal Investigators

  • Khadid Abd-Elaziz, MD · QPS Netherlands B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2022-05-19
Completion
2022-05-19

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307406 on ClinicalTrials.gov